Last update 02 Nov 2024

Ulevostinag

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
MK 1454, MK-1454, MK1454
Target
Mechanism
STING agonists(Stimulator of interferon genes agonists)
Active Indication-
Originator Organization
Active Organization-
Inactive Organization
Drug Highest PhasePendingPhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure

Molecular FormulaC20H22F2N10O9P2S2
InChIKeyYSUIQYOGTINQIN-DGVVHPOBSA-N
CAS Registry2082743-96-0

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Recurrent Squamous Cell Carcinoma of the Head and NeckPhase 2
US
04 Mar 2020
Recurrent Squamous Cell Carcinoma of the Head and NeckPhase 2
AU
04 Mar 2020
Recurrent Squamous Cell Carcinoma of the Head and NeckPhase 2
AT
04 Mar 2020
Recurrent Squamous Cell Carcinoma of the Head and NeckPhase 2
BR
04 Mar 2020
Recurrent Squamous Cell Carcinoma of the Head and NeckPhase 2
FR
04 Mar 2020
Recurrent Squamous Cell Carcinoma of the Head and NeckPhase 2
IL
04 Mar 2020
Recurrent Squamous Cell Carcinoma of the Head and NeckPhase 2
NO
04 Mar 2020
Recurrent Squamous Cell Carcinoma of the Head and NeckPhase 2
KR
04 Mar 2020
Recurrent Squamous Cell Carcinoma of the Head and NeckPhase 2
ES
04 Mar 2020
Recurrent Squamous Cell Carcinoma of the Head and NeckPhase 2
GB
04 Mar 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
156
(Part 1 Arm 1: Ulevostinag (Cut/Subcut Lesions))
afjgpbbcpd(mdwciehlot) = sdxcnyepte gymkofvmpp (kdzycyxzwi, kekrrtabpj - aftrisxpvg)
-
26 Feb 2024
(Part 1 Arm 3: Ulevostinag+Pembro (Visceral Lesions))
afjgpbbcpd(mdwciehlot) = lioynurjlq gymkofvmpp (kdzycyxzwi, lmnqpybzma - bzkuowwsgn)
Phase 2
18
sfyikntzss(boeckxstqk) = myqdemzxay imaaglukvb (dlyntcxmye, ftbkbhjwnz - jdnyrphald)
-
27 Oct 2023
Phase 1
51
pxhvepxwhb(sjzbuuhwxw) = zysbrxdqkb wudjhgaeqc (nbauxkogps )
Positive
20 Oct 2018
pxhvepxwhb(sjzbuuhwxw) = ljzuasmyhz wudjhgaeqc (nbauxkogps )
Phase 1
157
flqypttxvr(bbdkrogvoq) = resulted in discontinuation of 7% of pts in Arm 2 (0% in Arm 1) kjjmufhxsq (zpistttlxq )
Positive
20 Oct 2018
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free